相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms
Debra Van Egeren et al.
CELL STEM CELL (2021)
The Molecular Genetics of Myeloproliferative Neoplasms
Anna E. Marneth et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2020)
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions
Ruochen Jia et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms
Rasmus K. Pedersen et al.
CANCER MEDICINE (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations
Adrian Segura-Diaz et al.
CANCERS (2020)
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
Vibe Skov
CANCERS (2020)
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
Heinz Gisslinger et al.
HEMASPHERE (2020)
Loss of Dnmt3a Confers Resistance to Pegifna in JAK2-V617F Mouse Model
Jan Stetka et al.
BLOOD (2020)
Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension
Heinz Gisslinger et al.
BLOOD (2020)
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Sabrina Cordua et al.
BLOOD (2019)
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation
Julia Czech et al.
LEUKEMIA (2019)
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
B. Kubesova et al.
LEUKEMIA (2018)
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells
Josephine D. Kahn et al.
BLOOD (2018)
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
Ofir Wolach et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
Sebastien Jacquelin et al.
BLOOD (2018)
Accelerating myelofibrosis through loss of Dnmt3a
Radek C. Skoda
BLOOD (2018)
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
Joanne Hsu et al.
CELL STEM CELL (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
John Mascarenhas et al.
BLOOD (2018)
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
Christopher J. Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2017)
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
Lucia Masarova et al.
LANCET HAEMATOLOGY (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera
Cecilie Utke Rank et al.
LEUKEMIA & LYMPHOMA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
Lasse Kjaer et al.
PLOS ONE (2016)
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Andrew L. Young et al.
NATURE COMMUNICATIONS (2016)
Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing
A. Angona et al.
BLOOD CANCER JOURNAL (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
Erik Hulegardh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
Emmanuelle Verger et al.
BLOOD (2015)
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Jyoti Nangalia et al.
HAEMATOLOGICA (2015)
Effect of Mutation Order on Myeloproliferative Neoplasms
Christina A. Ortmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Jyoti Nangalia et al.
HAEMATOLOGICA (2015)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P. Guglielmelli et al.
LEUKEMIA (2014)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Alfonso Quintas-Cardama et al.
BLOOD (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
Thomas Stauffer Larsen et al.
LEUKEMIA RESEARCH (2013)
Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient
Nisha Rao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia
Elisabetta Antonioli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients
Emmanouil Spanoudakis et al.
ANNALS OF HEMATOLOGY (2009)
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden
Thomas Stauffer Larsen et al.
HEMATOLOGY (2009)
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
Thomas Stauffer Larsen et al.
HEMATOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera
T. S. Larsen et al.
ANNALS OF HEMATOLOGY (2008)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
Jean-Jacques Kiladjian et al.
BLOOD (2008)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a
Jean-Jacques Kiladjian et al.
BLOOD (2006)
A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia -: Feasibility, clinical and biologic effects, and impact, on quality of life
Jan Samuelsson et al.
CANCER (2006)
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
G Barosi et al.
BLOOD (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
分享论文
